A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)

Trial Profile

A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Tepotinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Acronyms VISION
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 07 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 30 Jun 2019.
    • 06 Jun 2017 Results (n=4) assessing safety and efficacy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Planned number of patients changed from 80 to 120.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top